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Abstract
Next-generation sequencing (NGS) technologies including DNA sequencing and RNA sequencing provide
“omics” approaches to reveal genomic, transcriptomic, and epigenomic landscapes of individual cancers. A variety
of genomic aberrations can be screened simultaneously, such as common and rare variants, structural variations
(e.g. insertions and deletions), copy-number variation, and fusion transcripts. NGS technologies together with
bioinformatics analysis, which expand our knowledge, are increasingly used to simultaneously analyze multiple
genes in a cost and time-effective manner and have been applied in analyzing clinical cancer samples and offering
NGS-based molecular diagnosis. Therefore, NGS is increasingly valuable as a tool for diagnosis for a number of
cancers. Here we briefly introduce NGS technologies and summarize the recent applications in cancer research and
molecular diagnosis in breast and prostate cancers.
Keywords Cancer; Next generation sequencing; Common variants;
Rare variants; Genome; Transcriptome; Epigenome; Diagnosis
Introduction
In the United States (US), more than 1.69 million new cancer cases
were diagnosed in 2016 [1]; while the global incidence of cancer was
about 14 million new cases in 2012 and an annual 19.3 million cases
will be expected by 2025 [2]. Family, twin, and adoption studies have
indicated that genetic and environmental factors and their interactions
contribute to the development of most cancers including breast, cervix,
colon, endocrine glands, prostate, testis and thyroid cancers, with a
heritability ranging from 20%-60% [3-6].
Genome-wide association study (GWAS) is a screening procedure
to identify the location of pathogenically relevant variations and
detects many common variants with small effects for cancers and other
complex diseases [6,7]. It is estimated that more than 100 common
variants with low risk may contribute to cancer susceptibility and other
complex diseases [6,8]; on the other hand, it has been suggested that
multiple rare variants may underlie susceptibility to common diseases/
traits including cancers; whereas the allelic architecture of complex
diseases/traits may be due to a combination of multiple common and
rare variants [9,10]. However, GWAS using tagSNPs are underpowered
for detecting associations with rare variants, although some rare
variants and haplotypes were identified; whereas rare and potentially
deleterious variants may not be detected by GWAS [11].
Next-generation sequencing (NGS) technology including DNA
sequencing and RNA sequencing, also known as massively parallel
sequencing, is increasingly used to detect sequence variations and has
provided abundant genetic markers including common and rare
variants and has been applied in the analysis of clinical cancer samples
including NGS-based molecular diagnosis [12-16]. NGS technologies
provide “omics” approaches to reveal genomic, transcriptomic, and
epigenomic landscapes of individual cancers [14,17]. The human
genomes obtain from the NGS technology have been a leap forward in
the fundamental understanding of human genetic variation for a
number of human diseases, treatment responses, including the genetic
variation in cancers.
NGS Applications in Cancer Research
DNA sequencing includes whole-genome sequencing (WGS),
whole-exome sequencing (WES), and targeted sequencing [14-16].
WGS allows sequencing of the entire cancer genomes (e.g., genomes of
the patients with cancers and/or cancer tissues), which can be used to
detect all types of somatic/germline including common and rare
variants, nucleotide substitutions, insertions and deletions, copy
number variations (CNVs), chromosomal rearrangements, as well as
analysis of the non-coding regions [7,15-19]. Three years ago, a study
reports that the sequencing of the genomes of all of the cancers in the
US is now theoretically feasible [20]. Currently, WGS holds great
potential for the rapid diagnosis for a number of cancers including
breast cancer (BC) [21]. WES focuses on the coding regions (exons) of
a genome, typically about 2% of the human genome, to discover rare or
common variants associated with a disorder or phenotype; therefore,
WES can be used to determine the sequence of the regulatory regions,
such as promoters and non–protein-coding regions, defining the
functional parts of the genome [15,18]; however, WES is not ideal for
the identification of CNVs and other structural alterations in the
genome [18]. Therefore, further targeted sequencing, focusing on a
selection of genes of interest for a specific disease identify by WES,
could be more accurate and accessible in terms of time and cost for
clinical applications for more laboratories [7,15,19]. WES promises to
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accelerate discovery of genetic causes and contributors of disease in
both the research and clinical settings [22]. WES also provides more
comprehensive in-depth exome sequencing to identify exact
pathogenic mutations for the diseased with a low frequency of false-
positive signals, which is a cost effective method (<$400-600/sample)
compared with whole genome sequencing (WGS) ($3000-5000/
sample) depending on the coverage [23]. In addition, precision cancer
medicine, the use of genetic/genomic profiles (e.g. NGS information)
of patient tumors at the point-of-care to inform treatment decisions, is
rapidly changing treatment strategies across cancer types. With the
knowledge of precision cancer medicine, we are able to increase
treatment efficacy, reduce toxicity, and therefore decrease overall cost
of cancer treatment for both individual family and society.
RNA sequencing (RNA-Seq) is to sequence the total RNA of the cell
to obtain information regarding mutations/single-nucleotide
polymorphisms (SNPs), splice variants, levels of gene expression, gene
fusions, genomic rearrangements, allele-specific expression,
posttranscriptional modifications, microRNAs, small and long
noncoding RNAs [12,16-18]. Gene expression, either alone or in
combination with mutational data, can also be used to investigate
spatial and temporal tumor heterogeneity [24].
The development of NGS technologies have made large-scale
projects such as The Cancer Genome Atlas (TCGA) [25] and the
International Cancer Genome Consortium (ICGC) [26] feasible, and
provided multi-platform data for thousands of tumors from a variety
of cancer types and subtypes and integrative analyses of genomic,
transcriptomic and epigenomic data and increase our understanding of
cancer biology [17,25,26]. For example, WES and WGS studies have
identified new high and moderate-risk genes in several types of
cancers, such as the pancreatic cancer susceptibility genes PALB2 and
ATM [27], and the hereditary colorectal cancer moderate-risk genes
POLD1 and POLE [28].
Non-coding RNA species such as microRNAs (miRNAs) and long
non-coding RNAs (lncRNAs) may also play important roles in a
variety of cellular processes, and have been shown to be widely
dysregulated in cancer [29]. MiRNAs can regulate the expression of
target genes and act as tumor suppressors or oncogenes and exert
widespread gene- and pathway-level effects [30]. Long non-coding
RNAs (lncRNAs) may play an important role in oncogenesis and
cancer pathology such as guiding the site specificity of chromatin-
modifying complexes or acting as regulators of protein signalling
pathways involved in carcinogenesis [17].
Epigenome alterations were also seen in a number of cancers such as
BC [31]. Among the epigenetic modifications, DNA methylation is
well documented and well-studied in cancer. Whole-genome bisulphite
sequencing (WGBS) or reduced representation bisulfite sequencing
(RRBS) has been used to identify methylated cytosines, especially in
the CpG islands, which are interspersed in the promoter and other
regulatory regions of a gene. Such epigenetic regulation mediated
through DNA methylation modulates the expression of certain genes
[16-18].
NGS Applications in Cancer Diagnosis
Although NGS is extensively used for cancer research field, lately
NGS technology has been applied in NGS-based cancer molecular
diagnosis [14-16,32]. Early detection and diagnosis will allow
effectively treatments, while NGS technology allows the simultaneous
sequencing of a large number of target genes and provides rich early
diagnostic markers to develop NGS-based molecular diagnosis
[13,15-17,33]. The advent of NGS has opened up many new frontiers.
For example, large-scale projects such as TCGA and the ICGC have
already made available data from thousands of tumors across major
cancer types, and have helped us refine cancer classification systems
and examine the interplay between DNA mutations, RNA expression,
and epigenomic patterns, obtaining a comprehensive overview of
cancer cells and providing enhanced diagnostic, prognostic, and
therapeutic criteria [14,17].
Targeted genetic tests are currently used as diagnostic and
prognostic tools in clinical oncology, and more extensive genomic tests
seem likely to come into regular use in the near future [34,35]; while
WES currently finds the most use in clinical diagnostics because it
covers more than 95% of the exons, which contains 85% of disease-
causing mutations [36]. WGS can be used to compare tumor
progression, treatment efficacy, the mechanisms associated with
resistance development; meanwhile, these can be the source for the
future, as new discoveries in clinically actionable alterations are made;
nevertheless, WGS incurs a high sequencing cost and computational
burden due to the amount of data produced, and alternate approaches
such as WES are also used for certain applications [15,18]. For
example, targeted cancer panels are advantageous due to their low cost
and relatively simple interpretability, and many exist both for specific
cancers, such as prostate cancer (PC) [37].
Recent advances in NGS technology have improved the
understanding of PC biology and clinical variability. Particularly,
DNA-Seq, RNA-Seq, chromatin immunoprecipitation-Seq, and
methyl-Seq experiments have identified some new recurrent
alterations in PC (e.g. TMPRSS2-ERG translocation, ATM, SPOP and
CHD1 mutations and chromoplexy) and have better elucidated the
major pathways affecting prostate tumorigenesis, which are the AR-
signaling, PI3K/PTEN/AKT, RB1, TP53 loss/mutations and RTK–Ras–
MAPK pathways [15,18,38]. However, at present, the study of multiple
genetic alterations in PC is not suggested for routine diagnostic
purposes; due to its highly heterogeneous nature of genetics and
phenotypes, PC continues to pose a tremendous challenge in terms of
diagnosis and prognosis [15,18]. Moreover, although ncRNAs are
considered as exciting new diagnostic, prognostic, and therapeutic
tools, additional work is needed to characterize the RNA species, their
functions, and their applicability to clinical practice in PC [39]. In
addition, a recent study found that stem cell and neurogenic gene-
expression profiles link prostate basal cells to aggressive PC using
prostate epithelial transcriptomes (a type of deep RNA sequencing
technology) [40].
Previous studies have shown that about 30% of BC cases are caused
by BRCA1 and BRCA2 mutations. Genetic test using BRCA1 and
BRCA2 mutations has been recommended; however, other genes such
as ATM, CHEK2, PALB2 and TP53, have been shown to confer high
BC risk [15,16]. For example, Lin et al developed a multiple gene
sequencing panel using the NGS, which contained 68 genes including
mutations in BRCA1 and BRCA2 genes, ATM, TP53; where the genes
in the panel had cancer risk association for patients with early-onset or
familial BC [33]. The multiple genes sequencing using the NGS is an
effective method to increase detected rate of high-risk cases [33]. Using
DNA methylation and miRNA profiles, a recent study reports that
DNA methylation contributes to deregulation of 12 cancer-associated
miRNAs and BC progression [41]. The authors also found a strong
association between hypermethylation of MIR-127 and MIR-125b-1
and BC progression, particularly metastasis and concluded that
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MIR-127 and MIR-125b-1 hypermethylation can be potential
biomarkers of BC metastasis. Moreover, a recent study using NGS
technology combined with protein expression identify PI3K pathway
aberrations are among the most common in cancers (including BC and
PC) by examining over 19784 consecutive tumor samples (>40 cancer
types) from thousands of clinicians in 60 countries [42]. The author
concluded that patterns of biomarker coalterations involving HER2
and hormone receptors may be important for optimizing combination
treatments across cancer types.
Concluding Remarks
NGS technology can be used to identify single nucleotide variants
(SNVs), multi nucleotide variants (MNVs), structural variations (SVs),
CNV, gene transcripts, epigenetic variations, and has led to
improvements in cancer classification systems and molecular diagnosis
[7,13,15-18]. Furthermore, the TCGA, ICGC and other groups have
conducted studies with multiple cancer types to integrate genomic,
transcriptomic, and epigenomic data from several cancer types and
have helped us refine classification systems as well as our general
understanding of cancer biology [15,17,25,26]. However, due to the
high costs, the need of complex bioinformatics pipelines, of large
storage capacity and the high number of variants, the clinical utility of
mutation discovery throughout the complete exome or genome
analysis is not convenient yet; furthermore, genetic diagnostics would
also benefit from RNA-seq approaches to allow the detection of a
higher number of mutations involved in disease onset and will aid in
improving personalised care and medical management [13,15,16]. The
effective applications of NGS in routine diagnostics rely on the high
discovery rate of new markers, increased clarity regarding the
validation and implementation of NGS tests and technological
improvements [13]. In the future, to better understand the genetic
etiology of cancers, to improve effective molecular diagnosis and to
apply for genome information in precision medicine, genomic
medicine and cancer clinic care, it will be useful to combine the results
of GWAS, gene-gene and gene-environment interactions, with the
recent rapid advances in NGS technologies including whole exome
sequencing, transcriptome sequencing, and whole genome sequencing.
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